PP Bionxt SolutionsNews - Page 1

BioNxt Solutions fast-tracks US patent for drug delivery platform

Partner News
BioNxt marks two key milestones in the expansion of its proprietary drug delivery platform targeting neurological autoimmune disorders.

Positive results for BioNxt’s cladribine sublingual thin-film

Partner News
BioNxt Solutions has announced successful formulation of a sublingual thin-film prototype for its lead clinical stage candidate, BNT23001.

BioNxt advances chemotherapy delivery platform to revolutionise cancer treatment

Partner News
BioNxt Solutions unveils a revolutionary chemotherapy delivery platform that targets tumours directly, boosting treatment effectiveness.

BioNxt’s sublingual cladribine solution ready for next phase of development

Partner News
BioNxt Solutions Inc. has announced the receipt of its thin-film formulation of sublingual cladribine for the treatment of multiple sclerosis.

BioNxt launches study for semaglutide oral thin film as alternative to injection/tablets

Partner News
BioNxt Solutions announces the launch of a feasibility study for the development of an oral dissolvable film (ODF) formulation of Semaglutide, a GLP-1 receptor agonist currently marketed globally under the brand names Ozempic®, Rybelsus®, and Wegovy®.

BioNxt Solutions expands research and development with Munich laboratory

Partner News
BioNxt Solutions' integration with Gen-Plus provides advanced research and development capabilities with a major biotech hub.

Innovation News Network - Free Digital eBook Library

Innovation News Network - Global Innovation Partners

Special Reports

Partner News

Special Reports Cont'd

Partner News Cont'd

Innovation News Network brings you the latest research and innovation news from the fields of science, environment, energy, critical raw materials, technology, and electric vehicles.

Science

Environment

Energy

Transport

Disclaimer: This website is an independent portal and is not responsible for the content of external sites.
Please Note: Phone calls may be recorded for training and monitoring purposes.
© Pan European Networks Ltd